- Home
- SWBI vs CELC Comparison
SWBI vs CELC Comparison
Compare SWBI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWBI
- CELC
- Stock Information
- Founded
- SWBI 1852
- CELC 2011
- Country
- SWBI United States
- CELC United States
- Employees
- SWBI N/A
- CELC N/A
- Industry
- SWBI Ordnance And Accessories
- CELC Medical Specialities
- Sector
- SWBI Industrials
- CELC Health Care
- Exchange
- SWBI Nasdaq
- CELC Nasdaq
- Market Cap
- SWBI 429.0M
- CELC 440.0M
- IPO Year
- SWBI N/A
- CELC 2017
- Fundamental
- Price
- SWBI $8.54
- CELC $13.63
- Analyst Decision
- SWBI Buy
- CELC Strong Buy
- Analyst Count
- SWBI 2
- CELC 6
- Target Price
- SWBI $12.00
- CELC $30.67
- AVG Volume (30 Days)
- SWBI 1.3M
- CELC 206.7K
- Earning Date
- SWBI 09-04-2025
- CELC 08-13-2025
- Dividend Yield
- SWBI 6.09%
- CELC N/A
- EPS Growth
- SWBI N/A
- CELC N/A
- EPS
- SWBI 0.30
- CELC N/A
- Revenue
- SWBI $474,661,000.00
- CELC N/A
- Revenue This Year
- SWBI $8.53
- CELC N/A
- Revenue Next Year
- SWBI N/A
- CELC N/A
- P/E Ratio
- SWBI $28.47
- CELC N/A
- Revenue Growth
- SWBI N/A
- CELC N/A
- 52 Week Low
- SWBI $8.38
- CELC $7.58
- 52 Week High
- SWBI $16.85
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- SWBI 36.14
- CELC 62.38
- Support Level
- SWBI $8.53
- CELC $12.48
- Resistance Level
- SWBI $8.85
- CELC $14.19
- Average True Range (ATR)
- SWBI 0.23
- CELC 0.75
- MACD
- SWBI -0.04
- CELC 0.07
- Stochastic Oscillator
- SWBI 20.54
- CELC 80.73
About SWBI Smith & Wesson Brands Inc.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.